Biolevate is a Paris-based health-tech company developing knowledge-driven automation for life sciences organisations. Its technology is designed to help pharmaceutical and other regulated healthcare companies handle complex information and documentation processes more efficiently.
The company’s platform supports activities such as medical writing, literature reviews, research synthesis and regulatory intelligence. Its objective is to reduce the manual work involved in processing large amounts of scientific and regulatory information while maintaining the evidence and traceability required in highly regulated industries.
The company was founded in 2023 by Joël Belafa and Nathan Chen. Its first major financing milestone came in November 2024, when Biolevate raised €6 million in seed funding led by EQT Ventures, with participation from Bpifrance and other investors.
This post covers:
- What Biolevate does and the problem it addresses
- Its funding journey from seed to Series A
- The role of private and public-backed investors
- What its September 2026 financing means for entrepreneurs
From a €6 million seed round to €30 million
The 2024 seed financing gave Biolevate capital to develop its AI platform and expand its team. At that stage, the company was addressing a relatively specific operational problem: helping medical writers and life sciences teams work with complex regulatory and scientific documentation.
The next stage came on 22 September 2026, when Biolevate announced a €30 million Series A. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F and existing investor EQT Ventures.
This brings the two publicly announced venture rounds to €36 million.
The composition of the Series A is notable because it combines venture investors with organisations closely connected to the healthcare and technology ecosystem. Orange described its investment as part of a broader effort to support trusted innovation in healthcare, while Biolevate said the financing would help it expand internationally and deepen its product capabilities.
The company is also expanding into the United States with a new office in Boston. According to Biolevate, it now has more than a dozen enterprise customers in production, has increased annual recurring revenue twentyfold over the previous twelve months and has doubled its workforce to 50 people.
The September financing is therefore not simply an extension of the initial product-development phase. It is connected to a broader international expansion strategy.
Public and private funding
Biolevate’s financing history combines private venture capital with participation from France’s public investment ecosystem.
The €6 million November 2024 seed round was led by EQT Ventures and included Bpifrance.
The €30 million September 2026 Series A was co-led by RAISE France and Orange Ventures, with MSD Global Health Innovation Fund, Station F and EQT Ventures participating.
The publicly disclosed financing therefore shows a progression from an early-stage round involving a public investment institution to a substantially larger Series A involving investors with strong links to healthcare, technology and the French innovation ecosystem.
What Biolevate’s funding journey shows
Biolevate’s trajectory highlights the importance of moving from a clearly defined operational problem to a broader platform opportunity.
The first financing focused on developing AI-assisted medical writing and expanding the team. By September 2026, the company was positioning its technology as an automation layer for a much wider range of regulated life sciences operations.
For entrepreneurs, this demonstrates why funding rounds often correspond to changes in the scale of the company’s proposition. Investors at an early stage may finance product development and initial validation, while a later round can support internationalisation, larger enterprise deployments and expansion into adjacent applications.
Biolevate’s journey also shows the value of building a financing network around a sector. Its investors span venture capital, public-backed investment, healthcare and technology organisations. For founders in regulated industries, strategic relevance can therefore be an important part of the funding story alongside technological development.
What entrepreneurs can take from it
A strong funding journey can develop in stages. Founders do not necessarily need to raise the largest possible amount at the beginning. Establishing the product, proving demand and creating evidence of adoption can provide the foundation for a larger round later.
Biolevate’s September 2026 Series A illustrates this progression: an initial €6 million seed investment was followed less than two years later by a €30 million round linked to international expansion and a significantly broader commercial ambition.
Entrepreneurs looking to understand how to identify funding opportunities, prepare fundraising strategies and combine different financing sources can also explore the Fundingtrip courses, which provide practical guidance for navigating the funding process.
About the author of this post
.
Sara Gavidia
Content Creator
Communications Manager & Content creator
LinkedIn
[email protected]
.
Hello! I’m Sara 👋🏻
I’m FundingTrip’s Content creator. I write posts about technology, funding and innovation. If you liked this one, subscribe to our newsletter to receive more updates!
Post reviewed by David Arias, funding expert.
